Anisodamine could decrease serum potassium levels in crush syndrome animals through activation of α7nAChR and downstream estradiol-induced enhancement of insulin sensitivity, manifested as an increase in serum estradiol which leads to the activation of tyrosine kinase on the insulin receptor, phosphoinositide 3-kinase, mammalian target of rapamycin, signal transducer and activator of transcription 3, and Na+/K+-ATPase (Yu et al., 2019; Fan et al., 2016) (Figure 1: Drugs treating hyperkalemia). The gene discussed is CHRNA7; the disease is Crush Syndrome.